Selected research
Market Analysis & Forecast
Global Companion Animal Pharmaceutical Market Analysis and Forecast 2026-2032
Market perspective
The global Companion Animal Pharmaceutical market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The North America market for Companion Animal Pharmaceutical is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
Europe market for Companion Animal Pharmaceutical is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
Read the full market overview
Asia-Pacific market for Companion Animal Pharmaceutical is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
The China market for Companion Animal Pharmaceutical is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
The major global companies of Companion Animal Pharmaceutical include Boehringer Ingelheim, Ceva, Dechra Veterinary Products, Elanco Animal Health, Meiji, Ouro Fino Saude, Parnell, Vetoquinol and Virbac, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.
Report Includes
This report presents an overview of global market for Companion Animal Pharmaceutical, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.
This report researches the key producers of Companion Animal Pharmaceutical, also provides the revenue of main regions and countries. Of the upcoming market potential for Companion Animal Pharmaceutical, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Companion Animal Pharmaceutical revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Companion Animal Pharmaceutical market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Companion Animal Pharmaceutical revenue, projected growth trends, production technology, application and end-user industry.
Companion Animal Pharmaceutical Segment by Company
Boehringer Ingelheim
Ceva
Dechra Veterinary Products
Elanco Animal Health
Meiji
Ouro Fino Saude
Parnell
Vetoquinol
Virbac
Zoetis
Bayer Animal Health
Merck Animal Health
Companion Animal Pharmaceutical Segment by Type
Infectious Diseases
Orthopedic Diseases
Dermatologic Diseases
Pain
Behavioral Diseases
Other Indications
Companion Animal Pharmaceutical Segment by Application
Dogs
Cats
Other
Companion Animal Pharmaceutical Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Companion Animal Pharmaceutical market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Companion Animal Pharmaceutical and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Companion Animal Pharmaceutical.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of Companion Animal Pharmaceutical in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Companion Animal Pharmaceutical company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Companion Animal Pharmaceutical revenue, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Infectious Diseases
- Orthopedic Diseases
- Dermatologic Diseases
- Pain
- Behavioral Diseases
- Other Indications
Applications
- Dogs
- Cats
- Other
Companies covered
- Boehringer Ingelheim
- Ceva
- Dechra Veterinary Products
- Elanco Animal Health
- Meiji
- Ouro Fino Saude
- Parnell
- Vetoquinol
- Virbac
- Zoetis
- Bayer Animal Health
- Merck Animal Health
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Companion Animal Pharmaceutical Market by Type
- 1.2.1 Global Companion Animal Pharmaceutical Market Size by Type, 2021 VS 2025 VS 2032
- 1.2.2 Infectious Diseases
- 1.2.3 Orthopedic Diseases
- 1.2.4 Dermatologic Diseases
- 1.2.5 Pain
- 1.2.6 Behavioral Diseases
- 1.2.7 Other Indications
- 1.3 Companion Animal Pharmaceutical Market by Application
- 1.3.1 Global Companion Animal Pharmaceutical Market Size by Application, 2021 VS 2025 VS 2032
- 1.3.2 Dogs
- 1.3.3 Cats
- 1.3.4 Other
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
2 Companion Animal Pharmaceutical Market Dynamics
- 2.1 Companion Animal Pharmaceutical Industry Trends
- 2.2 Companion Animal Pharmaceutical Industry Drivers
- 2.3 Companion Animal Pharmaceutical Industry Opportunities and Challenges
- 2.4 Companion Animal Pharmaceutical Industry Restraints
3 Global Growth Perspective
- 3.1 Global Companion Animal Pharmaceutical Market Perspective (2021-2032)
- 3.2 Global Companion Animal Pharmaceutical Growth Trends by Region
- 3.2.1 Global Companion Animal Pharmaceutical Market Size by Region: 2021 VS 2025 VS 2032
- 3.2.2 Global Companion Animal Pharmaceutical Market Size by Region (2021-2026)
- 3.2.3 Global Companion Animal Pharmaceutical Market Size by Region (2027-2032)
4 Competitive Landscape by Players
- 4.1 Global Companion Animal Pharmaceutical Revenue by Players
- 4.1.1 Global Companion Animal Pharmaceutical Revenue by Players (2021-2026)
- 4.1.2 Global Companion Animal Pharmaceutical Revenue Market Share by Players (2021-2026)
- 4.1.3 Global Companion Animal Pharmaceutical Players Revenue Share Top 10 and Top 5 in 2025
- 4.2 Global Companion Animal Pharmaceutical Key Players Ranking, 2024 VS 2025 VS 2026
- 4.3 Global Companion Animal Pharmaceutical Key Players Headquarters & Area Served
- 4.4 Global Companion Animal Pharmaceutical Players, Product Type & Application
- 4.5 Global Companion Animal Pharmaceutical Players Establishment Date
- 4.6 Market Competitive Analysis
- 4.6.1 Global Companion Animal Pharmaceutical Market CR5 and HHI
- 4.6.3 2025 Companion Animal Pharmaceutical Tier 1, Tier 2, and Tier 3
5 Companion Animal Pharmaceutical Market Size by Type
- 5.1 Global Companion Animal Pharmaceutical Revenue by Type (2021 VS 2025 VS 2032)
- 5.2 Global Companion Animal Pharmaceutical Revenue by Type (2021-2032)
- 5.3 Global Companion Animal Pharmaceutical Revenue Market Share by Type (2021-2032)
6 Companion Animal Pharmaceutical Market Size by Application
- 6.1 Global Companion Animal Pharmaceutical Revenue by Application (2021 VS 2025 VS 2032)
- 6.2 Global Companion Animal Pharmaceutical Revenue by Application (2021-2032)
- 6.3 Global Companion Animal Pharmaceutical Revenue Market Share by Application (2021-2032)
7 Company Profiles
- 7.1 Boehringer Ingelheim
- 7.1.1 Boehringer Ingelheim Company Information
- 7.1.2 Boehringer Ingelheim Business Overview
- 7.1.3 Boehringer Ingelheim Companion Animal Pharmaceutical Revenue and Gross Margin (2021-2026)
- 7.1.4 Boehringer Ingelheim Companion Animal Pharmaceutical Product Portfolio
- 7.1.5 Boehringer Ingelheim Recent Developments
- 7.2 Ceva
- 7.2.1 Ceva Company Information
- 7.2.2 Ceva Business Overview
- 7.2.3 Ceva Companion Animal Pharmaceutical Revenue and Gross Margin (2021-2026)
- 7.2.4 Ceva Companion Animal Pharmaceutical Product Portfolio
- 7.2.5 Ceva Recent Developments
- 7.3 Dechra Veterinary Products
- 7.3.1 Dechra Veterinary Products Company Information
- 7.3.2 Dechra Veterinary Products Business Overview
- 7.3.3 Dechra Veterinary Products Companion Animal Pharmaceutical Revenue and Gross Margin (2021-2026)
- 7.3.4 Dechra Veterinary Products Companion Animal Pharmaceutical Product Portfolio
- 7.3.5 Dechra Veterinary Products Recent Developments
- 7.4 Elanco Animal Health
- 7.4.1 Elanco Animal Health Company Information
- 7.4.2 Elanco Animal Health Business Overview
- 7.4.3 Elanco Animal Health Companion Animal Pharmaceutical Revenue and Gross Margin (2021-2026)
- 7.4.4 Elanco Animal Health Companion Animal Pharmaceutical Product Portfolio
- 7.4.5 Elanco Animal Health Recent Developments
- 7.5 Meiji
- 7.5.1 Meiji Company Information
- 7.5.2 Meiji Business Overview
- 7.5.3 Meiji Companion Animal Pharmaceutical Revenue and Gross Margin (2021-2026)
- 7.5.4 Meiji Companion Animal Pharmaceutical Product Portfolio
- 7.5.5 Meiji Recent Developments
- 7.6 Ouro Fino Saude
- 7.6.1 Ouro Fino Saude Company Information
- 7.6.2 Ouro Fino Saude Business Overview
- 7.6.3 Ouro Fino Saude Companion Animal Pharmaceutical Revenue and Gross Margin (2021-2026)
- 7.6.4 Ouro Fino Saude Companion Animal Pharmaceutical Product Portfolio
- 7.6.5 Ouro Fino Saude Recent Developments
- 7.7 Parnell
- 7.7.1 Parnell Company Information
- 7.7.2 Parnell Business Overview
- 7.7.3 Parnell Companion Animal Pharmaceutical Revenue and Gross Margin (2021-2026)
- 7.7.4 Parnell Companion Animal Pharmaceutical Product Portfolio
- 7.7.5 Parnell Recent Developments
- 7.8 Vetoquinol
- 7.8.1 Vetoquinol Company Information
- 7.8.2 Vetoquinol Business Overview
- 7.8.3 Vetoquinol Companion Animal Pharmaceutical Revenue and Gross Margin (2021-2026)
- 7.8.4 Vetoquinol Companion Animal Pharmaceutical Product Portfolio
- 7.8.5 Vetoquinol Recent Developments
- 7.9 Virbac
- 7.9.1 Virbac Company Information
- 7.9.2 Virbac Business Overview
- 7.9.3 Virbac Companion Animal Pharmaceutical Revenue and Gross Margin (2021-2026)
- 7.9.4 Virbac Companion Animal Pharmaceutical Product Portfolio
- 7.9.5 Virbac Recent Developments
- 7.10 Zoetis
- 7.10.1 Zoetis Company Information
- 7.10.2 Zoetis Business Overview
- 7.10.3 Zoetis Companion Animal Pharmaceutical Revenue and Gross Margin (2021-2026)
- 7.10.4 Zoetis Companion Animal Pharmaceutical Product Portfolio
- 7.10.5 Zoetis Recent Developments
- 7.11 Bayer Animal Health
- 7.11.1 Bayer Animal Health Company Information
- 7.11.2 Bayer Animal Health Business Overview
- 7.11.3 Bayer Animal Health Companion Animal Pharmaceutical Revenue and Gross Margin (2021-2026)
- 7.11.4 Bayer Animal Health Companion Animal Pharmaceutical Product Portfolio
- 7.11.5 Bayer Animal Health Recent Developments
- 7.12 Merck Animal Health
- 7.12.1 Merck Animal Health Company Information
- 7.12.2 Merck Animal Health Business Overview
- 7.12.3 Merck Animal Health Companion Animal Pharmaceutical Revenue and Gross Margin (2021-2026)
- 7.12.4 Merck Animal Health Companion Animal Pharmaceutical Product Portfolio
- 7.12.5 Merck Animal Health Recent Developments
8 North America
- 8.1 North America Companion Animal Pharmaceutical Revenue (2021-2032)
- 8.2 North America Companion Animal Pharmaceutical Revenue by Type (2021-2032)
- 8.2.1 North America Companion Animal Pharmaceutical Revenue by Type (2021-2026)
- 8.2.2 North America Companion Animal Pharmaceutical Revenue by Type (2027-2032)
- 8.3 North America Companion Animal Pharmaceutical Revenue Share by Type (2021-2032)
- 8.4 North America Companion Animal Pharmaceutical Revenue by Application (2021-2032)
- 8.4.1 North America Companion Animal Pharmaceutical Revenue by Application (2021-2026)
- 8.4.2 North America Companion Animal Pharmaceutical Revenue by Application (2027-2032)
- 8.5 North America Companion Animal Pharmaceutical Revenue Share by Application (2021-2032)
- 8.6 North America Companion Animal Pharmaceutical Revenue by Country
- 8.6.1 North America Companion Animal Pharmaceutical Revenue by Country (2021 VS 2025 VS 2032)
- 8.6.2 North America Companion Animal Pharmaceutical Revenue by Country (2021-2026)
- 8.6.3 North America Companion Animal Pharmaceutical Revenue by Country (2027-2032)
- 8.6.4 United States
- 8.6.5 Canada
9 Europe
- 9.1 Europe Companion Animal Pharmaceutical Revenue (2021-2032)
- 9.2 Europe Companion Animal Pharmaceutical Revenue by Type (2021-2032)
- 9.2.1 Europe Companion Animal Pharmaceutical Revenue by Type (2021-2026)
- 9.2.2 Europe Companion Animal Pharmaceutical Revenue by Type (2027-2032)
- 9.3 Europe Companion Animal Pharmaceutical Revenue Share by Type (2021-2032)
- 9.4 Europe Companion Animal Pharmaceutical Revenue by Application (2021-2032)
- 9.4.1 Europe Companion Animal Pharmaceutical Revenue by Application (2021-2026)
- 9.4.2 Europe Companion Animal Pharmaceutical Revenue by Application (2027-2032)
- 9.5 Europe Companion Animal Pharmaceutical Revenue Share by Application (2021-2032)
- 9.6 Europe Companion Animal Pharmaceutical Revenue by Country
- 9.6.1 Europe Companion Animal Pharmaceutical Revenue by Country (2021 VS 2025 VS 2032)
- 9.6.2 Europe Companion Animal Pharmaceutical Revenue by Country (2021-2026)
- 9.6.3 Europe Companion Animal Pharmaceutical Revenue by Country (2027-2032)
- 9.6.4 Germany
- 9.6.5 France
- 9.6.6 U.K.
- 9.6.7 Italy
- 9.6.8 Netherlands
- 9.6.9 Nordic Countries
10 China
- 10.1 China Companion Animal Pharmaceutical Revenue (2021-2032)
- 10.2 China Companion Animal Pharmaceutical Revenue by Type (2021-2032)
- 10.2.1 China Companion Animal Pharmaceutical Revenue by Type (2021-2026)
- 10.2.2 China Companion Animal Pharmaceutical Revenue by Type (2027-2032)
- 10.3 China Companion Animal Pharmaceutical Revenue Share by Type (2021-2032)
- 10.4 China Companion Animal Pharmaceutical Revenue by Application (2021-2032)
- 10.4.1 China Companion Animal Pharmaceutical Revenue by Application (2021-2026)
- 10.4.2 China Companion Animal Pharmaceutical Revenue by Application (2027-2032)
- 10.5 China Companion Animal Pharmaceutical Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
- 11.1 Asia Companion Animal Pharmaceutical Revenue (2021-2032)
- 11.2 Asia Companion Animal Pharmaceutical Revenue by Type (2021-2032)
- 11.2.1 Asia Companion Animal Pharmaceutical Revenue by Type (2021-2026)
- 11.2.2 Asia Companion Animal Pharmaceutical Revenue by Type (2027-2032)
- 11.3 Asia Companion Animal Pharmaceutical Revenue Share by Type (2021-2032)
- 11.4 Asia Companion Animal Pharmaceutical Revenue by Application (2021-2032)
- 11.4.1 Asia Companion Animal Pharmaceutical Revenue by Application (2021-2026)
- 11.4.2 Asia Companion Animal Pharmaceutical Revenue by Application (2027-2032)
- 11.5 Asia Companion Animal Pharmaceutical Revenue Share by Application (2021-2032)
- 11.6 Asia Companion Animal Pharmaceutical Revenue by Country
- 11.6.1 Asia Companion Animal Pharmaceutical Revenue by Country (2021 VS 2025 VS 2032)
- 11.6.2 Asia Companion Animal Pharmaceutical Revenue by Country (2021-2026)
- 11.6.3 Asia Companion Animal Pharmaceutical Revenue by Country (2027-2032)
- 11.6.4 Japan
- 11.6.5 South Korea
- 11.6.6 India
- 11.6.7 Australia
- 11.6.8 Taiwan
- 11.6.9 Southeast Asia
12 South America, Middle East and Africa
- 12.1 SAMEA Companion Animal Pharmaceutical Revenue (2021-2032)
- 12.2 SAMEA Companion Animal Pharmaceutical Revenue by Type (2021-2032)
- 12.2.1 SAMEA Companion Animal Pharmaceutical Revenue by Type (2021-2026)
- 12.2.2 SAMEA Companion Animal Pharmaceutical Revenue by Type (2027-2032)
- 12.3 SAMEA Companion Animal Pharmaceutical Revenue Share by Type (2021-2032)
- 12.4 SAMEA Companion Animal Pharmaceutical Revenue by Application (2021-2032)
- 12.4.1 SAMEA Companion Animal Pharmaceutical Revenue by Application (2021-2026)
- 12.4.2 SAMEA Companion Animal Pharmaceutical Revenue by Application (2027-2032)
- 12.5 SAMEA Companion Animal Pharmaceutical Revenue Share by Application (2021-2032)
- 12.6 SAMEA Companion Animal Pharmaceutical Revenue by Country
- 12.6.1 SAMEA Companion Animal Pharmaceutical Revenue by Country (2021 VS 2025 VS 2032)
- 12.6.2 SAMEA Companion Animal Pharmaceutical Revenue by Country (2021-2026)
- 12.6.3 SAMEA Companion Animal Pharmaceutical Revenue by Country (2027-2032)
- 12.6.4 Brazil
- 12.6.5 Argentina
- 12.6.6 Chile
- 12.6.7 Colombia
- 12.6.8 Peru
- 12.6.9 Saudi Arabia
- 12.6.10 Israel
- 12.6.11 UAE
- 12.6.12 Turkey
- 12.6.13 Iran
- 12.6.14 Egypt
13 Concluding Insights
14 Appendix
- 14.1 Reasons for Doing This Study
- 14.2 Research Methodology
- 14.3 Research Process
- 14.4 Authors List of This Report
- 14.5 Data Source
- 14.5.1 Secondary Sources
- 14.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst